within Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AA55_OxycodoneAndNaloxone;

model OxycodoneAndNaloxone
  extends Pharmacolibrary.Drugs.ATC.N.N02AA55;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02AA55</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oxycodone and naloxone (ATC N02AA55) is a fixed-dose combination opioid analgesic used for the management of severe pain, particularly in patients requiring long-term opioid therapy where opioid-induced constipation is a concern. Oxycodone acts primarily as a μ-opioid receptor agonist, while naloxone is a competitive opioid antagonist included to counteract opioid-induced constipation by local action in the gut. The oral combination is approved and used widely in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following repeated oral administration in healthy adults; mean values are primarily from published population PK studies of oxycodone/naloxone prolonged-release tablets.</p><h4>References</h4><ol><li><p>Thigpen, JC, et al., &amp; Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. <i>European journal of drug metabolism and pharmacokinetics</i> 44(5) 591–609. DOI:<a href=&quot;https://doi.org/10.1007/s13318-019-00552-0&quot;>10.1007/s13318-019-00552-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31006834/&quot;>https://pubmed.ncbi.nlm.nih.gov/31006834</a></p></li><li><p>Leppert, W (2014). Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. <i>Current drug targets</i> 15(1) 124–135. DOI:<a href=&quot;https://doi.org/10.2174/13894501113149990210&quot;>10.2174/13894501113149990210</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24020972/&quot;>https://pubmed.ncbi.nlm.nih.gov/24020972</a></p></li><li><p>Mercadante, S, &amp; Giarratano, A (2013). Combined oral prolonged-release oxycodone and naloxone in chronic pain management. <i>Expert opinion on investigational drugs</i> 22(1) 161–166. DOI:<a href=&quot;https://doi.org/10.1517/13543784.2013.752460&quot;>10.1517/13543784.2013.752460</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23215628/&quot;>https://pubmed.ncbi.nlm.nih.gov/23215628</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end OxycodoneAndNaloxone;
